Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:CASNumber |
2250033-82-6
|
| gptkbp:developedBy |
schizophrenia
|
| gptkbp:developer |
gptkb:Cerevel_Therapeutics
|
| gptkbp:hasMolecularFormula |
C19H21ClN2O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
emraclidine
|
| gptkbp:IUPACName |
1-(4-chlorophenyl)-N-[(3R)-3-methoxypiperidin-1-yl]-2-oxo-1,2-dihydro-3H-indole-3-carboxamide
|
| gptkbp:mechanismOfAction |
muscarinic M4 receptor positive allosteric modulator
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
in clinical trials
|
| gptkbp:synonym |
CVL-231
|
| gptkbp:bfsParent |
gptkb:Cerevel_Therapeutics
|
| gptkbp:bfsLayer |
6
|